Effects of PEG-rhGH on organ function of hypophysectomized rats
Pan-gui CHENG,Zhi-xin ZHANG,Lin PAN,Ying-ke LIN,Ye YANG,Qiu-ling ZHAO,Hong LI,Chun HE
DOI: https://doi.org/10.7501/j.issn.1674-5515.2014.11.006
2014-01-01
Abstract:Objective To investigate the effects of polyethylene glycol recombinant human growth hormone (PEG-rhGH) on the major organs of hypophysectomized rats. Methods Eighty-eight Sprague-Dawley young male rats were underwent hypophysectomy, and another 18 rats with Sham operations were selected into the control group. Fifty-four qualified rats were randomly divided into the model, rhGH, and PEG-rhGH groups after two weeks. Saline was used with sc administration at dosage of 0.25 mg/kg every night. Recombinant Human Growth Hormone for Injection (0.25 mg/kg) was sc given every night in rhGH group, but Polyethylene Glycol Recombinant Human Growth Hormone for Injection (1.40 mg/kg) was sc given in first night every week in PEG-rhGH group. After treatment for 4 weeks, Liver function such as ALT, AST, TBIL, and DBIL levels, renal function such as BUN and CREA levels, myocardial enzymes CK, CKMB, and liver, heart, kidney pathology transcription, and the protein expression of transforming growth factor-β1 (TGF-β1) and renal C-fos in liver tissue were determined. Results There were decrease of levels of AST and TBIL in liver function, but increase of CREA level in renal function. No obvious abnormalities of pathology in liver, kidney, and heart. There were no difference for hepatic TGF-β1 and the kidneys C-fos protein expression among groups. Conclusion No significant adverse effects of PEG-rhGH are observed on the liver, kidney, and heart morphology and function.